Insulin human (rDNA) biosimilar (Baxter)

人胰岛素（rDNA）生物类似药（百特）

Report date: 2022/07/14 20:00:44

Base Information

Drug NameInsulin human (rDNA) biosimilar (Baxter)
Drug Alias NameInpremziaMyxredlin
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/06/20
Country/TerritoryUnited StatesEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBaxter International Inc
China Registration ClassN/A

Develop Information

Active CompaniesBaxter Healthcare Corp
Inactive CompaniesBaxter Holding Bv
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A